X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (8) 8
female (7) 7
hematology (6) 6
male (6) 6
adult (5) 5
chronic lymphocytic-leukemia (5) 5
middle aged (4) 4
adolescent (3) 3
aged (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
brentuximab vedotin (3) 3
dermatology (3) 3
follicular lymphoma (3) 3
ibrutinib (3) 3
oncology (3) 3
open-label (3) 3
phase-ii (3) 3
plus rituximab (3) 3
retrospective studies (3) 3
young adult (3) 3
algorithm for treatment (2) 2
checkpoint inhibitors (2) 2
chemotherapy (2) 2
child (2) 2
infant (2) 2
infection (2) 2
iran - epidemiology (2) 2
non-hodgkin lymphoma (2) 2
novel therapies (2) 2
obinutuzumab (2) 2
outcomes (2) 2
research (2) 2
review (2) 2
risk factors (2) 2
single-arm (2) 2
skin (2) 2
united states - epidemiology (2) 2
women (2) 2
1st-line treatment (1) 1
4 ethnic-groups (1) 1
age (1) 1
age of onset (1) 1
aged, 80 and over (1) 1
allergens (1) 1
allergens - adverse effects (1) 1
allergens - immunology (1) 1
allergic contact dermatitis (1) 1
analysis of variance (1) 1
anti-cd20 monoclonal-antibody (1) 1
antibody-drug conjugate (1) 1
antibody–drug conjugate (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, alkylating - administration & dosage (1) 1
antineoplastic agents, alkylating - adverse effects (1) 1
antineoplastic agents, alkylating - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
apoptosis (1) 1
article subject (1) 1
atopic dermatitis (1) 1
audit (1) 1
basal cell carcinoma (1) 1
base-line series (1) 1
bcl2 (1) 1
bendamustine (1) 1
bendamustine hydrochloride - administration & dosage (1) 1
bendamustine hydrochloride - adverse effects (1) 1
bendamustine hydrochloride - therapeutic use (1) 1
biophysics (1) 1
biopsy - standards (1) 1
bleomycin - therapeutic use (1) 1
brain - abnormalities (1) 1
brain - virology (1) 1
cancer (1) 1
car t cell (1) 1
carcinoma, basal cell - diagnostic imaging (1) 1
carcinoma, basal cell - pathology (1) 1
carcinoma, basal cell - surgery (1) 1
care and treatment (1) 1
central nervous system diseases - epidemiology (1) 1
central nervous system diseases - virology (1) 1
child, preschool (1) 1
chromate (1) 1
cll (1) 1
cobalt (1) 1
cobalt - adverse effects (1) 1
cobalt - immunology (1) 1
color (1) 1
congenital abnormalities - epidemiology (1) 1
congenital abnormalities - virology (1) 1
cross-sectional studies (1) 1
cytotoxicity (1) 1
dacarbazine - therapeutic use (1) 1
denmark (1) 1
dentistry (1) 1
dermatitis, allergic contact - epidemiology (1) 1
dermatitis, allergic contact - immunology (1) 1
diagnosis (1) 1
dimension (1) 1
disease (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1720 - 1720
Abstract Background DLBCL is the most common non-Hodgkin lymphoma (NHL), making up about 30%-40% of NHL in the U.S. PET-CT is recommended as the most accurate... 
Journal Article
Journal Article
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, ISSN 0889-8588, 08/2019, Volume 33, Issue 4, pp. 727 - 727
Chemotherapy nonspecifically affects all cells undergoing DNA replication and has severe side effects. Understanding of the biology of non Hodgkin lymphomas... 
Targeted agents | R-CHOP | PLUS RITUXIMAB | BRENTUXIMAB VEDOTIN | IBRUTINIB | PHASE-II | Intracellular oncogenic pathways | FOLLICULAR LYMPHOMA | OPEN-LABEL | Non-Hodgkin lymphoma | ANTI-CD20 MONOCLONAL-ANTIBODY | THERAPY | ONCOLOGY | Monoclonal antibodies | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2813 - 2813
BACKGROUND FL is the most common indolent non-Hodgkin lymphoma (NHL). While very responsive to therapy, it has been considered incurable. Nonetheless, pts... 
Journal Article
Blood and lymphatic cancer : targets and therapy, ISSN 1179-9889, 2017, Volume 7, pp. 73 - 83
Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most... 
Chemotherapy | Usage | Care and treatment | Immunotherapy | Patient outcomes | Lymphomas | Cancer | Studies | Immunoglobulins | Response rates | Cytotoxicity | Apoptosis | Obinutuzumab | follicular lymphoma | monoclonal antibody | MRD
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 10/2017, Volume 17, Issue 10, pp. 637 - 644
Journal Article
The Scientific World Journal, ISSN 1537-744X, 2012, Volume 2012, pp. 386936 - 5
Background. Understanding the physiological, chemical, and biophysical characteristics of the skin helps us to arrange a proper approach to the management of... 
WOMEN | 4 ETHNIC-GROUPS | SEBUM CONTENT | SURFACE PH | COLOR | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | TRANSEPIDERMAL WATER-LOSS | FACIAL SKIN | HUMAN FACE | STRATUM-CORNEUM HYDRATION | Skin Physiological Phenomena | Young Adult | Humans | Middle Aged | Adolescent | Adult | Female | Male | Biophysics | Child | Physiological aspects | Physiological research | Skin | Research | Parameters | Hydration | Elasticity | Gender | Males | Forehead | Water loss | Skin diseases | Erythema | Females | Age | Melanin
Journal Article
International Journal of Hematologic Oncology, ISSN 2045-1393, 06/2017, Volume 6, Issue 1, pp. 13 - 24
Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved... 
ibrutinib | immune checkpoint inhibitor | antibody-drug conjugate | CAR T cell | follicular lymphoma | PET-CT | minimal residual disease | idelalisib | lenalidomide | obinutuzumab | antibody–drug conjugate | Review
Journal Article
Expert review of hematology, 10/2018, Volume 11, Issue 10, p. 773
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e14027 - e14027
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 10/2018, Volume 11, Issue 10, pp. 773 - 780
Introduction: Hodgkin's lymphoma (HL) accounts for about 10% of all lymphomas in the U.S.A. Exceptional progress has been made in the treatment of HL with... 
algorithm for treatment | checkpoint inhibitors | relapsed Hodgkin's lymphoma | Hodgkin's lymphoma | brentuximab vedotin | novel therapies | PRIMARY RESISTANT | PHASE-II | FOLLOW-UP | STAGE-III | SINGLE-ARM | CHEMOTHERAPY | DISEASE | SALVAGE THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 4_suppl, pp. 46 - 46
46 Background: Gastric and esophageal adenocarcinomas (GA and EA) in young patients (pts) are more likely driven by genetic factors than environmental... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4311 - 4311
Introduction: Acalabrutinib (acala) is an irreversible, second generation Bruton tyrosine kinase inhibitor (BTKi) approved by the FDA for the treatment of... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1553 - 1553
Introduction: A positive interim PET scan (PET2) following 2 cycles of ABVD for Hodgkin lymphoma (HL) is associated with a poor prognosis; several studies in... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1756 - 1756
BACKGROUND Novel agents have changed the treatment landscape in chronic lymphocytic leukemia (CLL), however little has been reported about real-world treatment... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3048 - 3048
BACKGROUND The recent approval of novel agents (NAs) has changed the treatment landscape in chronic lymphocytic leukemia (CLL), however, there remains... 
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 14, pp. 4264 - 4270
Purpose: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL)... 
ONCOLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | OUTCOMES
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.